An Indiana CDMO with big-name clients sets up plans for lentiviral production site

Josh Sullivan

An Indiana CDMO focused on gene therapy is cashing in on the industry’s hot streak and unveiling a master plan for a 75,000-square-foot lentiviral vector …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

An Indiana CDMO with big-name clients sets up plans for lentiviral production site

Josh Sullivan

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

An In­di­ana CD­MO with big-name clients sets up plans for lentivi­ral pro­duc­tion site

Josh Sullivan

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

An Indiana CDMO with big-name clients sets up plans for lentiviral production site

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life